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We thank Manji and colleagues for
their comments on our article, ‘‘Car-
diac xenotransplantation technology
provides materials for improved bio-
prosthetic heart valves.’’ There is
growing consensus that ectopic calci-
fication, including calcification of bio-
prosthetic heart valves, may occur in
response to local inflammatory reac-
tions.1 Our research, which builds on
earlier fundamental findings that
show glutaraldehyde fixed biopros-
thetic materials are not totally immu-
nologically inert,2,3 sought to identify
a potential clinically relevant
mechanism for such inflammation
and suggests that anti-Gal antibody
binding to bioprosthetic materials
may be one such signal. As indicated
in the article, our work is consistent
with the clinical histopathology of ex-
planted porcine valves derived from
left ventricular assist devices and
extends the earlier observations that
antibody from sensitized serum could
accelerate calcification.4 This work
and our earlier study5 using Gal-
positive and Gal-deficient fixed por-
cine pericardium show that naturalThe Journalpreformed anti-Gal antibody is suffi-
cient to accelerate the calcification
process in the subcutaneous implant
model. This suggests, but does not
conclusively prove, that a preformed
anti-Gal antibody–mediated inflam-
matory response may occur soon after
implantation and that such an
antibody-mediated inflammation may
initiate an innate immune response
that furthers calcification of the de-
vice. The a1,3-galactosyltransferase
gene-knockout (GT-KO) pig, which
makes anti-Gal antibody, is an appro-
priate model to test this hypothesis
because implantation of Gal-positive
bioprosthetic materials would repre-
sent an allogeneic implant that differs
from the recipient only by the pres-
ence of aGal sugar. Our results sup-
port the use of GT-KO tissues for
valve development as a means to de-
bulk the major antigen. It may also
be of interest to determine if the early
inflammatory response is blocked,
whether other clinical modalities that
block antibody-induced inflammation
could further forestall degeneration
of bioprosthetic heart valves.
In their letter, Manji and colleagues
suggest that additional genetic modifi-
cation of bioprosthetic materials,
including complement regulatory pro-
teins and antithrombotic functions,
might be incorporated to further pre-
vent valve degradation. We agree that
incorporation of these functions in liv-
ing tissues may help to prevent rejec-
tion of xenogeneic organs or tissues.
The high level of glutaraldehyde fixa-
tion used in the preparation of biopros-
thetic valves, however, would likely
inactivate the function of these pro-
teins, thereby eliminating any potential
protection to the bioprosthetic valve.
We agree that under the current reg-
ulations the cost of bioprosthetic heart
valves from genetically modified
sources would likely be increased
compared with wild-type pigs. It
seems likely that the level of biosecur-
ity, which significantly affects the cost
of production, needed for fixed valve
tissue would be lower than the highof Thoracic and Cardiovascular Surgelevel of biocontainment required by
regulatory agencies to produce live
tissues and organs for xenotransplan-
tation. If genetically modified valves
have greater durability, then the addi-
tional cost of the valve will be offset
by the benefit to the patient and use
in a potentially expanded younger pa-
tient population and might be further
offset by future regulatory changes
governing the disposition of geneti-
cally modified animal tissues.
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